Facts and Figures
Leading in the Conquest of Cancer
The following statistics help illustrate what sets the U-M Rogel Cancer Center's faculty, staff and programs apart as Leaders and Best™ in cancer. But numbers can tell only part of the story. Click on any link below to read the stories behind the numbers.
The company we keep
- The U-M Rogel Cancer Center is one of only 49 centers in the United States to earn the National Cancer Institute's "comprehensive" designation. This prestigious designation reflects our wide-ranging research initiatives, including translating new discoveries from the laboratory to our patients. We also conduct research to better prevent or control cancer and provide patient education, community outreach and training for tomorrow's cancer experts.
- The cancer center is also a founding member of the National Comprehensive Cancer Network, a consortium of 27 of the nation's premier centers, which develops national guidelines for the delivery of effective, quality care.
- Among more than 900 hospitals considered, the University of Michigan ranks 12th on the U.S. News list of best hospitals for cancer - Michigan is ranked number 1 in Michigan for cancer care.
Confidence that comes with experience
Ours is among the largest clinical enterprises in cancer. Patients meet with multidisciplinary teams in one of 17 multidisciplinary and 10 specialty clinics, organized by cancer type.
Here's a snapshot of our 2017 clinical activities:
- 103,966 outpatient visits
- 56,910 infusion treatments
- 4,590 radiation consults
- 3,498 cancer patients discharged from university hospitals
These numbers mean our patients benefit from having experienced, knowledgeable doctors, nurses and other clinical experts involved in diagnosing and treating every patient's case, from the most common to the rarest and most complex.
The top 5 cancers diagnosed and treated at the University of Michigan:
U-M has been recognized by the national Blue Cross Blue Shield Association as a Blue Distinction Center for Complex and Rare Cancers® for our work within 13 cancer center programs:
- Acute Leukemia - Inpatient, Non-Surgical
- Bladder Cancer
- Bone Cancer - Primary
- Brain Cancer - Primary
- Esophageal Cancer
- Gastric Cancer
- Head and Neck Cancer
- Liver Cancer - Primary
- Pancreatic Cancer
- Ocular Melanoma
- Rectal Cancer
- Soft Tissue Sarcomas
- Thyroid Cancer- Medullary and/or Anaplastic
Putting Patients and Families First
Our commitment to the conquest of cancer is surpassed only by our commitment to treating patients like members of our own family. How are we doing?
Our cancer center Patient Satisfaction statistics confirm that we excel - and continue to improve - in caring for patients and families:
- 2004 = 88%
- 2006 = 89%
- 2008 = 90%
- 2010 = 90%
- 2012 = 92%
- 2013 = 95%
- 2014 = 96%
- 2015 = 96%
- 2016 = 96%
- 2017 = 96%
Because we understand the impact cancer has on every life it touches, we invest in staff and programs to reduce the burden of cancer for patients and those who love them:
- Our Patient and Family Support Services (PFSS) Program currently offers more than 30 programs and services led by specialists in psychology, social work, art therapy, nutrition, finance, and other areas.
- Staffed by registered oncology nurses, the U-M Cancer AnswerLine provides toll-free access to personalized information on the entire spectrum of cancer issues, helping individuals navigate the complexities of the health care system and connect with support groups and community resources. In fiscal year 2017, the Cancer AnswerLine™ responded to 8,824 inquiries.
Volume and Outcome
At Michigan Medicine, our goal is to become the national leader in health care quality and safety. The Rogel Cancer Center is doing its part in this effort. For information about our quality of care, choose one of the options below:
Quality of care measures for other types of cancer will be added in the near future.
Research: more insights, more options
The U-M Rogel Cancer Center consistently ranks in the top 11 nationally in grant funding from the National Cancer Institute. Our medical school currently ranks sixth on that list.
Michigan receives more than $100 million in grants annually from the NCI and other agencies.
More than 500 U-M faculty members provide care to cancer patients and collaborate on laboratory, clinical, prevention and outcomes research.
Michigan is home to a Specialized Program of Research Excellence (SPORE), in gastrointestinal cancers. This significant, multi-year NCI research grant focuses on prevention, early detection, diagnosis and treatment of gastrointestinal cancers. In addition, as a member of the Sarcoma Alliance for Research through Collaboration (SARC), the cancer center's Sarcoma Program plays a pivotal role in one of only two SPORE grants focused on sarcoma.
Our patients are the most important beneficiaries of Michigan's vigorous commitment to research. Through more than 358 active cancer-related clinical trials, patients have access to the very latest treatment advances, often before they are available in the community.
Serving our community and yours
The Rogel Cancer Center Community Outreach Program works to educate public audiences about cancer prevention, early detection and screening. Last year, the Outreach Team participated in more than 70 community events.
We maintain a speaker's bureau of experts available to participate in local educational and outreach events.